Scott Alexander
2026.03.16
47% relevant
The post includes an advertisement for Nectome, a startup offering a $100,000 pre‑sale to preserve whole bodies (claiming nanoscale, subsynaptic fidelity, stable at room temperature), which exemplifies a broader trend where speculative, high‑risk biological technologies are commercialized to consumers before clear regulatory, ethical, or safety frameworks exist.
Razib Khan
2026.03.14
62% relevant
Bradley warns that current innovation is increasingly limited by the regulatory state rather than science or funding, and Matter Bio’s push toward human trials illustrates the mismatch between rapid translational progress and governance that the existing idea captures.